Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.

PARPi ataxia-telangiectasia mutation (ATM) brain metastasis breast cancer precision medicine

Journal

Journal of immunotherapy and precision oncology
ISSN: 2590-017X
Titre abrégé: J Immunother Precis Oncol
Pays: United States
ID NLM: 101768397

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 02 11 2022
revised: 23 02 2023
accepted: 09 05 2023
medline: 28 8 2023
pubmed: 28 8 2023
entrez: 28 8 2023
Statut: epublish

Résumé

Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except

Identifiants

pubmed: 37637237
doi: 10.36401/JIPO-22-33
pmc: PMC10448731
doi:

Types de publication

Case Reports

Langues

eng

Pagination

158-161

Déclaration de conflit d'intérêts

Conflict of Interest: None.

Références

NPJ Breast Cancer. 2019 Nov 29;5:46
pubmed: 31815182
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
Eur Urol. 2021 Feb;79(2):200-211
pubmed: 33176972
Cancers (Basel). 2020 Mar 14;12(3):
pubmed: 32183301
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):31-40
pubmed: 28816158
Handb Clin Neurol. 2018;149:27-42
pubmed: 29307358
J Clin Oncol. 2004 Sep 1;22(17):3608-17
pubmed: 15337811
Eur Urol. 2019 Oct;76(4):452-458
pubmed: 30797618
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Ann Transl Med. 2018 May;6(9):163
pubmed: 29911111
Nat Rev Urol. 2019 Jan;16(1):4-6
pubmed: 30498248
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
J Neuroimaging. 2015 May-Jun;25(3):474-81
pubmed: 25060327
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054

Auteurs

Anca Chelariu-Raicu (A)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center, and CCC Munich, LMU University Hospital, Munich, Germany.

Sarina A Piha-Paul (SA)

Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Mariana Chavez-MacGregor (M)

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jason Johnson (J)

Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Raymond Sawaya (R)

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mary Frances McAleer (MF)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Alissa Nguyen (A)

Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Audrey Hartnett (A)

Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Apostolia M Tsimberidou (AM)

Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Funda Meric-Bernstam (F)

Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Department of Breast Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ecaterina E Dumbrava (EE)

Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Classifications MeSH